CervoMed Inc. Common Stock (CRVO)

Price$2.94

Value ScoreC

Growth ScoreD

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-78.35%

Price vs S&P 500 (4W)-25.56%

VGM Score33.05

Market Capitalization$27.22M

All Metrics

Book Value / Share (Quarterly)$1.15

P/TBV (Annual)2.80x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)418.15%

Cash Flow / Share (Quarterly)$-2.98

Price vs S&P 500 (YTD)-70.94%

Gross Margin (TTM)-230.43%

Net Profit Margin (TTM)-1056.59%

EPS (TTM)$-3.27

10-Day Avg Trading Volume0.07M

EPS Excl Extra (TTM)$-3.27

Revenue Growth (5Y)61.03%

EPS (Annual)$-2.98

ROI (Annual)-147.98%

Gross Margin (Annual)100.00%

Net Profit Margin (5Y Avg)-1248.36%

Cash / Share (Quarterly)$1.40

Revenue Growth QoQ (YoY)-99.60%

ROA (Last FY)-117.87%

Revenue Growth TTM (YoY)-78.55%

EBITD / Share (TTM)$-3.39

ROE (5Y Avg)-73.02%

Operating Margin (TTM)-1100.61%

Cash Flow / Share (Annual)$-2.53

P/B Ratio2.56x

P/B Ratio (Quarterly)3.44x

Net Income / Employee (Annual)$-1,797,800

EV / Revenue (TTM)9.23x

Net Interest Coverage (TTM)-612.33x

ROA (TTM)-112.62%

EPS Incl Extra (Annual)$-2.98

Current Ratio (Annual)4.91x

Quick Ratio (Quarterly)3.00x

3-Month Avg Trading Volume0.07M

52-Week Price Return-61.01%

Revenue / Employee (TTM)$139,300

Tangible BV / Share (Quarterly)$1.69

P/S Ratio (Annual)6.79x

Asset Turnover (Annual)0.18x

52-Week High$13.13

Operating Margin (5Y Avg)-4529.28%

EPS Excl Extra (Annual)$-2.98

Tangible BV CAGR (5Y)28.99%

26-Week Price Return-70.42%

Quick Ratio (Annual)4.65x

13-Week Price Return-26.68%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)3.36x

Enterprise Value$19.28M

Asset Turnover (TTM)0.07x

Book Value / Share Growth (5Y)-60.98%

Revenue / Employee (Annual)$267,100

Inventory Turnover (Annual)2.00x

Pretax Margin (Annual)-673.06%

Cash / Share (Annual)$2.25

3-Month Return Std Dev67.18%

Gross Margin (5Y Avg)-108.48%

Net Income / Employee (TTM)$-2,002,400

ROE (Last FY)-147.98%

Net Interest Coverage (Annual)18.75x

EPS Basic Excl Extra (Annual)$-2.98

Receivables Turnover (TTM)13.33x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-3.27

Receivables Turnover (Annual)8.00x

ROI (TTM)-136.08%

P/S Ratio (TTM)13.03x

Pretax Margin (5Y Avg)-1247.28%

Revenue / Share (Annual)$0.44

Tangible BV / Share (Annual)$14.87

Price vs S&P 500 (52W)-85.37%

Year-to-Date Return-62.78%

5-Day Price Return-2.00%

EPS Normalized (Annual)$-2.98

ROA (5Y Avg)-62.00%

Net Profit Margin (Annual)-673.06%

Month-to-Date Return-5.47%

Cash Flow / Share (TTM)$-1.84

EBITD / Share (Annual)$-3.13

Operating Margin (Annual)-706.22%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-73.02%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-3.27

P/TBV (Quarterly)5.91x

P/B Ratio (Annual)4.01x

Inventory Turnover (TTM)0.00x

Pretax Margin (TTM)-1056.59%

Book Value / Share (Annual)$1.97

Price vs S&P 500 (13W)-34.94%

Beta-0.59x

Revenue / Share (TTM)$0.23

ROE (TTM)-136.08%

52-Week Low$2.81

vGradeC

gGradeD

mGradeD

vgmGradeD

Show chart for

Earnings Surprise History

Q1 26-0.86est. -0.80

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.07

4.08

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
CRVOCervoMed Inc. Common Stock	C	D	D	$2.94
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

CervoMed is a clinical-stage biotechnology company developing treatments for age-related neurological disorders. Its lead candidate, Neflamapimod, is designed to address synaptic dysfunction in dementia with Lewy bodies and related neurological conditions.